Sector consensus Perspective Therapeutics, Inc.
Stocks
CATX
US46489V3024
Biotechnology & Medical Research
|
Market Closed -
NYSE
04:00:00 2026-09-02 pm EDT
|
5-day change | 1st Jan Change | ||
| 3.100 USD | 0.00% |
|
-1.90% | +12.73% |
| Aug. 19 | BMO Capital Initiates Perspective Therapeutics at Outperform | MT |
| Aug. 14 | BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6 | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 12.36 | +298.62% | 14 | ||||||
| 681.13 | +17.88% | 23 | ||||||
| 248.77 | +18.54% | 21 | ||||||
| 276.28 | +6.94% | 18 | ||||||
| 432.16 | +20.49% | 28 | ||||||
| 266,031.64 | +41.51% | 23 | ||||||
| 270.77 | +20.62% | 20 | ||||||
| 581.83 | -0.24% | 12 | ||||||
| 72.53 | +1.35% | 14 | ||||||
| 281 | -0.47% | 14 | ||||||
| 185.56 | +14.97% | 16 | ||||||
| 65.79 | +5.65% | 14 | ||||||
| 70.73 | -2.01% | 11 | ||||||
| 49.79 | +16.88% | 11 | ||||||
| 138.97 | +41.16% | 6 | ||||||
| 134.85 | -0.17% | 11 | ||||||
| 88 | +46.96% | 22 | ||||||
| 134.09 | +12.63% | 22 | ||||||
| 638.68 | +80.71% | 19 | ||||||
| 174.69 | +19.25% | 13 | ||||||
| Average | 13,528.48 | +33.06% | 17 | ||||||
| Weighted average by Cap. | 23,426.38 | +18.78% | 19 |
- Stock Market
- Stocks
- CATX Stock
- Sector Perspective Therapeutics, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
